Clinical Trials supported by Real World Evidence are transformative tools that use patient-level data to better assess the value of treatments and services based on actual health outcomes and the total cost of care. Patients receive treatment and are assessed in a “Real World” clinical setting to help measure the efficacy of treatments.
CBD Science is pioneering the development of cannabis-based treatments for cancer pain. We are working with world-class physicians, and Britain’s official regulatory authorities to allow the legal availability of new pain treatments, through our Real-World Evidence studies.
RWE can provide a window into how therapies perform differentially across endpoints and subpopulations, against expectations and against existing solutions. The generation of comparable data sets will develop into valuable marketing assets. Assets used to drive for patient, clinician, regulators and payer’s buy-in.
Real data. Real patients. Data sources related to patient health statusand/or the historic health profile collected from a variety of sources. These sources provide reliable evaluations on three pillars of RWE Studies. Humanistic Data, Clinical Data & Economic Data.
Real-world performance will enable individual management solutions this will lead to the development of better product profiles and performance thresholds. This will advise the payer value conversation and in turn position CBD Science to capture an ever-growing share of the pain management market.